Related Experiment Video
Updated: May 21, 2026
04:47
A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
Published on: February 23, 2018
Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
Robert F Kelley1, Y Gloria Meng
1Antibody Engineering, Genentech Inc, South San Francisco, CA, USA.
Methods in Molecular Biology (Clifton, N.J.)
|June 23, 2012
Summary
Researchers engineered therapeutic antibodies (Immunoglobulin G subclass 1) to improve half-life and efficacy. Protocols were developed to generate and test Fc-engineered antibodies for enhanced FcRn binding and effector functions, potentially improving patient treatment convenience and outcomes.
Area of Science:
- Biotechnology
- Immunology
- Pharmacology
Background:
- Therapeutic antibodies, particularly Immunoglobulin G subclass 1 (IgG1), are widely used due to their antigen-binding specificity and affinity.
- The Fc portion of IgG1 antibodies is crucial for long serum half-life via FcRn receptor interaction and for mediating effector functions through Fcγ receptors and complement.
- Enhancements to the Fc portion could improve therapeutic antibody efficacy and patient convenience through optimized dosing and increased effectiveness.
Purpose of the Study:
- To describe protocols for generating Fc-engineered IgG1 antibodies with potentially improved properties.
- To establish assays for measuring key Fc-mediated functions, including FcRn binding, Fcγ receptor binding, and cytotoxic activities.
- To identify engineered antibody variants with enhanced FcRn binding for extended half-life or improved effector functions for increased therapeutic potency.
Main Methods:
- Development of protocols for engineering the Fc region of IgG1 antibodies.
- Implementation of assays to quantify FcRn receptor binding affinity.
- Assessment of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities.
- Evaluation of Fcγ receptor binding capabilities.
Main Results:
- Protocols for generating Fc-engineered IgG1 antibodies were successfully established.
- Assays were validated to measure FcRn binding, Fcγ receptor interactions, and cytotoxic effector functions (ADCC and CDC).
- The developed methods enable the identification of Fc variants with potentially superior pharmacokinetic (e.g., FcRn binding) and pharmacodynamic (effector functions) profiles.
Conclusions:
- Fc engineering represents a viable strategy to enhance the therapeutic potential of IgG1 antibodies.
- The described protocols and assays provide a framework for developing next-generation therapeutic antibodies with improved half-life and effector functions.
- Optimized Fc-engineered antibodies hold promise for more convenient dosing and increased clinical efficacy in patients.
